Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SNS-301 in ASPH+ High Risk MDS and CMML
NCT04217720Phase 2Withdrawn
- Sponsor
- Sensei Biotherapeutics
- Start
- Apr 2020
- Primary completion
- Jan 2022
- Modality
- Nanoparticles, Vaccines & Immunotherapeutics, Single Strain Products
01
Overview
A Phase 2 trial of SNS-301 in myelodysplastic syndrome (MDS), chronic myelomonocytic leukemia (CMML), sponsored by Sensei Biotherapeutics. Planned start Apr 2020; status: withdrawn.
02
Drugs
SNS-301
03
Conditions
myelodysplastic syndrome (MDS)chronic myelomonocytic leukemia (CMML)
Beyond the preview
Go deeper on NCT04217720.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04217720.